Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Threshold Glufosfamide Phase III Results Delayed Until 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Pivotal pancreatic cancer study moving slower than projected because patients are living longer, firm says.

You may also be interested in...



Threshold Reports "Encouraging" Phase II Glufosfamide Data For Use With Gemzar

Initial safety analysis of pancreatic cancer trial shows a "slightly higher" incidence of nephrotoxicity with the combination regimen compared to individual use of either drug.

Threshold Reports "Encouraging" Phase II Glufosfamide Data For Use With Gemzar

Initial safety analysis of pancreatic cancer trial shows a "slightly higher" incidence of nephrotoxicity with the combination regimen compared to individual use of either drug.

One Door Closes For TH-070, But Another May Open, Threshold Says

The company discontinued development of drug for BPH, but will explore other potential uses.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel